Compare · ICLR vs MEDP
ICLR vs MEDP
Side-by-side comparison of ICON plc (ICLR) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICLR and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.21B, about 1.3x ICLR ($12.94B).
- MEDP has been more active in the news (13 items in the past 4 weeks vs 4 for ICLR).
- Both have 25 recent analyst ratings on file.
- Company
- ICON plc
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $12.94B
- $17.21B
- 1M return
- -
- -0.03%
- 1Y return
- -
- +17.91%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1998
- 2016
- News (4w)
- 4
- 13
- Recent ratings
- 25
- 25
ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest ICLR
- ICON plc upgraded by BofA Securities with a new price target
- SEC Form 6-K filed by ICON plc
- ICON Schedules Third Quarter 2026 Earnings Conference Call
- UBS resumed coverage on ICON plc with a new price target
- Director Mccague Eugene Pacelli exercised 3,255 units of Ordinary Shares at a strike of $125.74 and sold $569,625 worth of Ordinary Shares (3,255 units at $175.00) (SEC Form 4)
- Director Climax John Dr exercised 5,005 units of Ordinary Shares at a strike of $125.74 and sold $875,875 worth of Ordinary Shares (5,005 units at $175.00) (SEC Form 4)
- Director Murphy Ronan Martin exercised 5,005 units of Ordinary Shares at a strike of $125.74 and sold $875,875 worth of Ordinary Shares (5,005 units at $175.00) (SEC Form 4)
- SEC Form 6-K filed by ICON plc
- SEC Form 6-K filed by ICON plc
- SEC Form 6-K filed by ICON plc
Latest MEDP
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)
- President & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)
- UBS resumed coverage on Medpace with a new price target
- President & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)